Adjuvant Pembrolizumab Continues to Provide Survival Benefit in Stage IIB/C Melanoma
Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis-free vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma